Table 3.
Clinical features of patient undergone surgical management with curative intent after radiotherapy and locoregional therapy.
| Patient | Age/sex | Etiology | Maximum HCC | PVTT | Treatments | Radiotherapy of PVTT | Overall Responses | Surgical managements | Outcomes | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Duration | Dose (Gy) | Response | ||||||||||
| 1 | 48 Y/M | HBV | 2.0 cm | Left PV (Vp3) | Radiotherapy TACE/RFA | 45 days | 29 | CR | CR | DDLT | 123.9 ms | Alive |
| 2 | 59 Y/M | HCV | 4.5 cm | Right PV (Vp3) | Radiotherapy TACE | 24 days | 6 | CR | CR | LDLT | 77.5 ms | Death |
| 3 | 49 Y/F | HBV | 2.8 cm | Right PV (Vp2) | Radiotherapy TACE | 45 days | 20 | CR | PR | LDLT | 57.2 ms | Alive |
| 4 | 77 Y/M | HBV | 4.7 cm | Left PV (Vp3) | Radiotherapy TACE/UFT | 35 days | 13 | SD | PR | Left hepatectomy | 9.8 ms | Death |
| 5 | 60 Y/M | No | 6.0 cm | Right PV (Vp2) | Radiotherapy TACE | 45 days | 22 | PR | SD | Extended right hepatectomy | 12.26 ms | Death |
| 6 | 51 Y/M | HBV | 4.4 cm | Left PV (Vp2) | Radiotherapy TACE | 45 days | 21 | CR | CR | DDLT | 52.1 ms | Alive |
Y: years old; M: male; F: female; HBV: hepatitis B virus; HCV: hepatitis C virus; HCC: hepatocellular carcinoma; PV: portal vein; PVT: portal vein tumor thrombosis; TACE: transcatheter arterial chemoembolization; RFA: radiofrequency ablation; UFT: tegafur & uracil; CR: complete response; PR: partial response; SD: stable disease; PD: progression disease; DDLT: decease donor liver transplantation; LDLT: living donor liver transplantation; ms: months.